Adeel Masood

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Systematic Review

Hematopoietic Stem Cell

Multiple Myeloma

Top Venues

Annals of hematology

Clinical case reports

American journal of hematology

Bone marrow transplantation

This page only lists publications with an associated author ORCID identifier.

Publications

Oren Pasvolsky, Denái R Milton, Adeel Masood, Sophiya S Sami, Mark R Tanner, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Arsalan Saeed, Hans C Lee, Krina K Patel, Partow Kebriaei, Sheeba K Thomas, Donna M Weber, Robert Z Orlowski, Elizabeth J Shpall, Richard E Champlin, Muzaffar H Qazilbash
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. American journal of hematology (2023)
Adeel Masood, Qamar Iqbal, Hamid Ehsan, James A Davis, Doris K Hansen, Hamza Hashmi
Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature. Annals of hematology 101 (12) (2022)
Adeel Masood, Ahsan Wahab, Qamar Iqbal, James A Davis, Hamid Ehsan, Hamza Hashmi
Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature. Bone marrow transplantation 57 (6) (2022)
Adeel Masood, Hamid Ehsan, Qamar Iqbal, Ahmed Salman, Hamza Hashmi
Treatment of Light Chain Deposition Disease: A Systematic Review. Journal of hematology 11 (4) (2022)
Adeel Masood, Ahsan Wahab, Tanya Clifford, Eric J Weaver, Hamid Ehsan, Walid El Ayass
Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report. Clinical case reports 9 (12) (2021)
Karun Neupane, Ahsan Wahab, Adeel Masood, Tehniat Faraz Ahmed, Saman Bahram, Hamid Ehsan, Abdul Hannan, Faiz Anwer
Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma. Journal of blood medicine 12 (2021)